Aquestive Therapeutics to Present at Two Upcoming Investor Conferences
January 04 2021 - 7:30AM
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical
company focused on developing and commercializing differentiated
products that address patients’ unmet needs and solve therapeutic
problems, announced today that the management team will participate
in fireside chats at the H.C. Wainwright BioConnect 2021 Conference
to be held virtually January 11-14, and at the Westwicke Healthcare
Day to be held virtually on January 14 during the ICR Conference
2021. Aquestive will host one-on-one investor meetings during the
week of January 11 in conjunction with the ICR Conference.
Presentation times and availabilities are as follows:
H.C. Wainwright BioConnect 2021
ConferenceAvailable on demand from January 11 - 14
Westwicke Healthcare Day at ICR Conference
2021Thursday, January 14 at 2:30 pm ET
Webcasts of the fireside chats will be available
on the "Events and Presentation" page of the Investors section of
the Company's website. A replay of webcast will be available for 30
days following the event. For more information, please visit
investors.aquestive.com.
About Aquestive
TherapeuticsAquestive Therapeutics is a pharmaceutical
company that applies innovative technology to solve therapeutic
problems and improve medicines for patients. The Company has
commercialized one internally-developed proprietary product to
date, Sympazan®, has a commercial proprietary product pipeline
focused on the treatment of diseases of the central nervous system,
or CNS, and other unmet needs, and is developing orally
administered complex molecules to provide alternatives to
invasively administered standard of care therapies. The Company
also collaborates with other pharmaceutical companies to bring new
molecules to market using proprietary, best-in-class technologies,
like PharmFilm®, and has proven capabilities for drug development
and commercialization.
Forward-Looking
StatementsCertain statements in this press release are
“forward-looking statements” made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include any statement that does not
directly relate to any historical or current fact. Forward-looking
statements are based on our current expectations and assumptions,
which may not prove to be accurate. These statements are not
guarantees and are subject to risks, uncertainties, and changes in
circumstances that are difficult to predict, and significant
contingencies, many of which are beyond the Company's control.
Important factors that could cause actual results to differ
materially from these forward-looking statements are detailed in
the Company’s Annual Report on Form 10 K, in our Quarterly Reports
on Form 10-Q, and in our Current Reports on Form 8-K filed with the
Securities Exchange Commission (SEC). Given those uncertainties,
you should not place undue reliance on these forward-looking
statements, which speak only as of the date made. All subsequent
forward-looking statements attributable to us or any person acting
on our behalf are expressly qualified in their entirety by this
cautionary statement. The Company assumes no obligation to update
or revise any forward-looking statements or outlook or guidance
after the date of this press release whether as a result of new
information, future events or otherwise, except as may be required
by applicable law.
PharmFilm®, Sympazan® and the Aquestive logo are
registered trademarks of Aquestive Therapeutics, Inc.
Investor inquiries:Stephanie
Carringtonstephanie.carrington@westwicke.com646-277-1282
Aquestive Therapeutics (NASDAQ:AQST)
Historical Stock Chart
From Apr 2024 to May 2024
Aquestive Therapeutics (NASDAQ:AQST)
Historical Stock Chart
From May 2023 to May 2024